New Drug Doubles Pancreatic Cancer Survival Rates

For decades, doctors called them "undruggable." Now, a new treatment is proving them wrong and giving hope to thousands of pancreatic cancer patients.

A groundbreaking RAS inhibitor has approximately doubled overall survival rates compared to standard chemotherapy for patients with metastatic pancreatic cancer. The breakthrough targets KRAS mutations, genetic changes present in more than 90% of the most common type of pancreatic cancer.

Scientists have known about KRAS mutations since the 1980s, but creating drugs to stop them seemed impossible. The protein's smooth surface gave medications nothing to grab onto, earning it the "undruggable" label that frustrated researchers for generations.

Recent clinical trials have shattered that barrier. The new inhibitor works by blocking the mutated KRAS protein from sending signals that help cancer cells grow and spread.

The Pancreatic Cancer Action Network is hosting educational webinars to help patients understand KRAS testing and new treatment options. Dr. Anna Berkenblit, the organization's Chief Scientific and Medical Officer, leads sessions explaining what these mutations mean and how patients can access biomarker testing.

Over 90% of people diagnosed with pancreatic ductal adenocarcinoma have a KRAS mutation in their tumor. Knowing whether you carry this mutation now opens doors to targeted treatments that weren't available even a few years ago.

Why This Inspires

This breakthrough represents more than just one successful drug. It proves that "impossible" problems can be solved with persistent research and innovation.

Terri Conneran, a lung cancer survivor and patient advocate who founded KRAS Kickers, participates in these educational efforts alongside leading researchers. Her involvement shows how patients are becoming partners in pushing science forward and demanding better treatment options.

Clinical trials continue testing additional KRAS inhibitors and combination therapies. Each study builds on these initial successes, working toward even better outcomes for future patients.

The research also extends beyond pancreatic cancer. KRAS mutations appear in lung cancer, colorectal cancer, and other difficult-to-treat diseases, meaning millions of patients could eventually benefit from these advances.

Patients diagnosed today have options their predecessors never imagined possible.

---

##